$CRVO
CervoMed Inc.

2017 Q3 Form 10-Q Financial Statement

#000143774917019012 Filed on November 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.560M $3.850M
YoY Change -59.48% 816.67%
% of Gross Profit
Research & Development $1.759M $1.942M
YoY Change -9.4% 110.55%
% of Gross Profit
Depreciation & Amortization $30.00K $10.00K
YoY Change 200.0% 85.43%
% of Gross Profit
Operating Expenses $1.759M $1.942M
YoY Change -9.4% -85.32%
Operating Profit -$3.346M -$5.800M
YoY Change -42.31% 330.76%
Interest Expense $1.318K $1.378K
YoY Change -4.35% -98.19%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income $5.097M -$5.801M
YoY Change -187.86% 307.79%
Income Tax -$364.8K
% Of Pretax Income
Net Earnings $5.097M -$5.437M
YoY Change -193.75% 282.15%
Net Earnings / Revenue
Basic Earnings Per Share $0.21 -$0.53
Diluted Earnings Per Share $0.20 -$0.53
COMMON SHARES
Basic Shares Outstanding 13.94M 10.33M
Diluted Shares Outstanding 14.71M 10.33M

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.220M $3.020M
YoY Change -59.6% -79.29%
Cash & Equivalents $1.216M $3.021M
Short-Term Investments
Other Short-Term Assets $11.02M $270.0K
YoY Change 3981.48% -74.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.24M $3.287M
YoY Change 272.45% -78.97%
LONG-TERM ASSETS
Property, Plant & Equipment $479.6K $85.58K
YoY Change 460.49% 35.0%
Goodwill $6.929M $6.929M
YoY Change 0.0% 603.48%
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $38.81K $106.6K
YoY Change -63.58%
Total Long-Term Assets $16.09M $15.76M
YoY Change 2.07% 103.41%
TOTAL ASSETS
Total Short-Term Assets $12.24M $3.287M
Total Long-Term Assets $16.09M $15.76M
Total Assets $28.33M $19.05M
YoY Change 48.72% -18.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $409.4K $757.5K
YoY Change -45.95% 215.11%
Accrued Expenses $1.420M $1.040M
YoY Change 36.54% -41.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $550.0K $1.880M
YoY Change -70.74%
Total Short-Term Liabilities $18.69M $3.681M
YoY Change 407.73% 80.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $550.0K
YoY Change -100.0%
Other Long-Term Liabilities $49.93K
YoY Change
Total Long-Term Liabilities $0.00 $49.93K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.69M $3.681M
Total Long-Term Liabilities $0.00 $49.93K
Total Liabilities $21.97M $7.561M
YoY Change 190.59% 75.46%
SHAREHOLDERS EQUITY
Retained Earnings -$63.34M -$57.62M
YoY Change 9.94% -39.98%
Common Stock $69.70M $69.10M
YoY Change 0.86% -39.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.357M $11.49M
YoY Change
Total Liabilities & Shareholders Equity $28.33M $19.05M
YoY Change 48.72% -18.53%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $5.097M -$5.437M
YoY Change -193.75% 282.15%
Depreciation, Depletion And Amortization $30.00K $10.00K
YoY Change 200.0% 85.43%
Cash From Operating Activities -$3.890M -$1.860M
YoY Change 109.14% 89.8%
INVESTING ACTIVITIES
Capital Expenditures -$380.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$380.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.940M 1.880M
YoY Change -203.19%
NET CHANGE
Cash From Operating Activities -3.890M -1.860M
Cash From Investing Activities -380.0K 0.000
Cash From Financing Activities -1.940M 1.880M
Net Change In Cash -6.210M 20.00K
YoY Change -31150.0% -102.04%
FREE CASH FLOW
Cash From Operating Activities -$3.890M -$1.860M
Capital Expenditures -$380.0K $0.00
Free Cash Flow -$3.510M -$1.860M
YoY Change 88.71% 89.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
88175
CY2016Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
220978
CY2017Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
CY2016Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-18909792
dffn Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
CY2017Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
28891
dffn Makewhole Provision Conversion Price Percentage
MakewholeProvisionConversionPricePercentage
1.05
dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
CY2016Q3 dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
dffn Dilutive Securities Effect On Basic Earnings Per Share Interest On Convertible Debt
DilutiveSecuritiesEffectOnBasicEarningsPerShareInterestOnConvertibleDebt
CY2017Q3 dffn Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
2891861
CY2016Q3 dffn Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-5436553
dffn Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-4067127
dffn Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-15465912
CY2017Q3 dffn Preferential Dividends Payble
PreferentialDividendsPayble
725774
CY2016Q4 dffn Preferential Dividends Payble
PreferentialDividendsPayble
CY2017Q3 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
1004361
CY2016Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
50844
CY2017Q3 dffn Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
844521
CY2016Q4 dffn Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
12725
CY2017Q3 dffn Previously Capitalized Offering Costs Expensed During The Period
PreviouslyCapitalizedOfferingCostsExpensedDuringThePeriod
98000
dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
22129774
dffn Proceeds From Issuance Of Convertible Preferred Stock Net Of Offering Costs
ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts
dffn Proceeds From Reverse Merger Transaction
ProceedsFromReverseMergerTransaction
dffn Proceeds From Reverse Merger Transaction
ProceedsFromReverseMergerTransaction
8500602
dffn Stock Reclassified Upon Conversion Of Preferred Stock
StockReclassifiedUponConversionOfPreferredStock
187172
CY2017Q3 dffn Warrant Expense
WarrantExpense
CY2016Q3 dffn Warrant Expense
WarrantExpense
dffn Warrant Expense
WarrantExpense
10225846
dffn Warrant Expense
WarrantExpense
dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
5813720
dffn Warrant Expense Change In Fair Value And Other Financing Expenses
WarrantExpenseChangeInFairValueAndOtherFinancingExpenses
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-336852
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1024196
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
409423
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1684158
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
114268
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
72855
CY2017Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
398859
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
399740
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
69686744
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
69363575
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
28017
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
973950
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
292501
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
390357
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
973950
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1121990
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11967
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7067
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16529812
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3231148
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3212188
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3231148
CY2017Q3 us-gaap Assets
Assets
28327243
CY2016Q4 us-gaap Assets
Assets
17484384
CY2017Q3 us-gaap Assets Current
AssetsCurrent
12240525
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1603696
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1216000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1552852
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1997192
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3021388
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
10020164
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
CY2017Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14003608
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14503976
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10345637
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14503976
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10345637
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
14504
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
10346
CY2017Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
550000
CY2016Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1880000
CY2017Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
CY2016Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
550000
CY2017Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
550000
CY2017Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
550000
CY2016Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2430000
CY2017Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
550000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1880000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
711495
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-364796
CY2017Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3279363
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3279363
us-gaap Depreciation
Depreciation
39767
us-gaap Depreciation
Depreciation
19520
CY2017Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
27374
CY2016Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
5822
us-gaap Depreciation Nonproduction
DepreciationNonproduction
39767
us-gaap Depreciation Nonproduction
DepreciationNonproduction
19520
CY2017Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
16316054
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
us-gaap Dividends
Dividends
912946
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8441616
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18909792
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2017Q3 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
2.22
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y182D
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.093
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Fair Value Assumptions Weighted Average Expected Dividend
FairValueAssumptionsWeightedAverageExpectedDividend
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
21261000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6761
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1559399
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3852406
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4908424
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10070878
CY2017Q3 us-gaap Goodwill
Goodwill
6929258
CY2016Q4 us-gaap Goodwill
Goodwill
6929258
CY2017Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5096856
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5801349
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3154181
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15830708
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-364796
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-364796
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1496150
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
410014
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
661675
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-50918
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
816579
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
756376
CY2016Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
20608
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22976919
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15465912
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3346078
CY2017Q3 us-gaap Liabilities
Liabilities
21970547
CY2016Q4 us-gaap Liabilities
Liabilities
8299700
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28327243
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17484384
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18691184
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4438422
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2500000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
CY2017Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2016Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1318
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1378
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-73290
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-854
us-gaap Interest Paid Net
InterestPaidNet
112800
us-gaap Interest Paid Net
InterestPaidNet
CY2017Q3 us-gaap Interest Payable Current
InterestPayableCurrent
36029
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
29359
CY2017Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
36000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
50000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1409363
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-left:0.6%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:top;width:9%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td style="vertical-align:top;width:91%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Organization and Description of Business</div></div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:8pt;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">Diffusion Pharmaceuticals Inc. (&#x201c;Diffusion&#x201d; or the &#x201c;Company&#x201d;), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, trans sodium crocetinate (&#x201c;TSC&#x201d;) for use in many cancer types in which tumor oxygen deprivation (&quot;hypoxia&quot;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">&#x2019;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. The U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) provided Diffusion with final protocol guidance for a Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> trial of TSC in newly diagnosed inoperable GBM patients and the Company plans to begin the trial by the end of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:8pt;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 8, 2016, </div>the Company completed a reverse merger (the &#x201c;Merger&#x201d;) with RestorGenex Corporation (&#x201c;RestorGenex&#x201d;) whereby the Company was considered the acquirer for accounting purposes. The operational activity of RestorGenex is included in the Company<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">&#x2019;s consolidated financial statements from the date of acquisition. Accordingly, all comparative period information presented in these unaudited condensed consolidated financial statements from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2016 </div>through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 7, 2016 </div>exclude any activity related to RestorGenex.</div></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20151794
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1880000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10438604
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8498271
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10050042
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9354075
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
5096856
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-5436553
us-gaap Net Income Loss
NetIncomeLoss
-3154181
us-gaap Net Income Loss
NetIncomeLoss
-15465912
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2891861
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5436553
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4067127
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15465912
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2920752
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5436553
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5799971
us-gaap Operating Income Loss
OperatingIncomeLoss
-8894611
us-gaap Operating Income Loss
OperatingIncomeLoss
-15829854
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
547724
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
27746
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
118519
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
116464
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
114409
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
112354
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
58232
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1415707
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
874264
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38813
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
232675
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31915
CY2017Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
CY2016Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2870226
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
CY2017Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
33107
CY2016Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
28388
CY2017Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
52602
CY2016Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
151332
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
97980
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
438604
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2331
us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
10000000
us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
CY2017Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
366641
CY2016Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
912946
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
CY2017Q3 us-gaap Prepaid Insurance
PrepaidInsurance
126733
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
9731
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1880000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
479647
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79755
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
1880000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1759305
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1941743
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3946420
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5739456
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
951000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63344552
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60189237
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
340041
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2207409
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2545989
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.09
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.49
us-gaap Share Based Compensation
ShareBasedCompensation
973950
us-gaap Share Based Compensation
ShareBasedCompensation
1121990
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1746809
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1461
CY2017Q3 us-gaap Share Price
SharePrice
1.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y226D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y135D
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
50000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
6356696
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
9184684
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9184684
CY2017Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6356696
CY2017Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
16814360
CY2016Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2017Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2017Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
13750000
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12376329
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
8324032
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1838354
CY2016Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:44pt;">The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim condensed consolidated financial statements in the period they are deemed necessary.</div></div></div>
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14714853
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10333898
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12525707
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10198491
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13937869
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10333898
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11709128
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10198491

Files In Submission

Name View Source Status
0001437749-17-019012-index-headers.html Edgar Link pending
0001437749-17-019012-index.html Edgar Link pending
0001437749-17-019012.txt Edgar Link pending
0001437749-17-019012-xbrl.zip Edgar Link pending
dffn-20170930.xml Edgar Link completed
dffn-20170930.xsd Edgar Link pending
dffn-20170930_cal.xml Edgar Link unprocessable
dffn-20170930_def.xml Edgar Link unprocessable
dffn-20170930_lab.xml Edgar Link unprocessable
dffn-20170930_pre.xml Edgar Link unprocessable
dffn20170930_10q.htm Edgar Link pending
dffn20170930_10qimg002.jpg Edgar Link pending
ex_100329.htm Edgar Link pending
ex_100330.htm Edgar Link pending
ex_100331.htm Edgar Link pending
ex_100333.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending